Characteristics | Survivors (n = 177) | Non-survivors (n = 159) | P-value |
---|---|---|---|
Demographics | |||
 Male, No. (%) | 128 (72.3) | 122 (76.7) | .36 |
 Age, median (IQR), years | 70 (67–72) | 69 (66–72) | .64 |
 Acquired in ICU, No. (%) | 91 (51.4) | 90 (56.6) | .34 |
 Previous ICU admission | 127 (71.8) | 110 (69.2) | .61 |
 Length of hospitalization before bacteremia, median (IQR), days | 36 (24–48) | 35 (27–44) | .98 |
Comorbidities, No. (%) | |||
 Charlson co-morbidity score | 3.8 (3.4–4.2) | 3.9 (3.5–4.2) | .75 |
  Malignancy | 50 (28.3) | 44 (27.7) | .91 |
  Solid tumor | 42 (23.7) | 30 (18.9) | .28 |
  Hematologic malignancy | 8 (4.5) | 21 (13.2) | .005 |
 Type 2 diabetes mellitus | 63 (35.6) | 44 (27.7) | .12 |
 Cerebrovascular accident | 47 (26.6) | 21 (13.2) | .002 |
 Hypertension | 85 (48.0) | 65 (40.9) | .19 |
 Immunosuppressant use | 35 (19.8) | 56 (35.2) | .001 |
 Liver cirrhosis | 19 (10.7) | 14 (8.8) | .55 |
 Chronic kidney disease | 58 (32.8) | 62 (39.0) | .23 |
 Coronary artery disease | 29 (16.4) | 24 (15.1) | .75 |
 Congestive heart failure | 34 (19.2) | 34 (21.4) | .62 |
 Chronic obstructive pulmonary disease | 39 (22.0) | 33 (20.8) | .78 |
 Collagen vascular disease | 10 (5.7) | 18 (11.3) | .06 |
 Chemotherapy | 13 (7.3) | 21 (13.2) | .08 |
 Neutropenia | 8 (4.5) | 13 (8.2) | .17 |
 Recent surgery | 64 (36.2) | 32 (20.1) | .001 |
Invasive procedures, No. (%)a | |||
 Arterial line | 63 (35.6) | 69 (43.4) | .14 |
 Central venous catheter | 111 (62.7) | 113 (71.1) | .11 |
 Hemodialysis | 21 (11.9) | 26 (16.4) | 024 |
 Tracheostomy | 44 (24.9) | 50 (31.5) | .18 |
 Ventilator (previous use) | 73 (41.2) | 92 (57.9) | .002 |
 Ventilator (current use) | 121 (68.4) | 121 (76.1) | .12 |
 Ventilator associated pneumonia | 121 (68.4) | 113 (71.1) | .59 |
Clinical condition | |||
 APACHE II score within 24 h before bacteremia, median (IQR) | 23 (21–24) | 33 (32–35) | <.001 |
 Shock | 75 (42.4) | 75 (47.2) | .38 |
Resistance profiles of bloodstream isolates, No. (%) | |||
 Multidrug resistance (MDR)b | 156 (88.1) | 150 (94.3) | .046 |
 Carbapenem resistance | 104 (58.8) | 129 (81.1) | <.001 |
 Extensive drug resistance (XDR)c | 58 (32.8) | 95 (59.8) | <.001 |
Appropriate antimicrobial therapy | 94 (53.1) | 57 (35.9) | .001 |